Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall sentiment reflects mild interest and engagement, exemplified by comments like '@blueeyedboy88 Mam bezdech ale czytałam' which shows personal health relevance, and mentions of the publication's design and baseline characteristics, indicating a basic level of engagement. The tone is neutral and informational, with some users indicating a desire to learn more, but overall, the discussions suggest cautious recognition rather than strong enthusiasm or skepticism.
Most discussions appear to acknowledge the study's importance or mention it factually, without strong disagreement or critique.
Participants show some curiosity about the subject, responding with brief mentions of their experiences or plans to read more.
Comments include references to personal health impacts and mentions of the study's design, indicating moderate active participation.
The discussions suggest an awareness of potential implications for treatment of sleep apnea, though few details indicate deep concern or widespread change.
@ConscienHealth -Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial. Contemp Clin Trials. 2024.
@bfialek Cierpię to czytałem https://t.co/kYwao4mqMx
Bibliografía en @PubMedOnline Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial Atul Malhotra et al. Contemp Clin Trials. 2024 Jun. https://t.co/Hm7RwgRgL7
RT @Obesidades_mx: @ConscienHealth -Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sam…
Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial https://t.co/Nchel08Az6
@blueeyedboy88 Mam bezdech ale … czytałem https://t.co/kYwao4mqMx
This video discusses the potential of tirzepatide for treating obesity-related obstructive sleep apnea, based on the SURMOUNT-OSA phase 3 trial evaluating its safety and effectiveness over 52 weeks.
The clinical trial demonstrates that tirzepatide reduces the severity of obstructive sleep apnea and improves cardiometabolic parameters in obese patients after 52 weeks, offering a promising pharmacological option.
RT @Obesidades_mx: @ConscienHealth -Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sam…
@ConscienHealth -Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial. Contemp Clin Trials. 2024.
Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial https://t.co/Nchel08Az6
@blueeyedboy88 Mam bezdech ale … czytałem https://t.co/kYwao4mqMx
@bfialek Cierpię to czytałem https://t.co/kYwao4mqMx
Bibliografía en @PubMedOnline Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial Atul Malhotra et al. Contemp Clin Trials. 2024 Jun. https://t.co/Hm7RwgRgL7